Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163962 | 0.85 | MAOA (0.50) | MAOAMAOBL3MBTL1 | |
| SCHEMBL28910971 | 0.82 | SRD5A2 (0.52) | ALDH1A1SMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL14042627 | 0.82 | FNTA (0.53) | L3MBTL1 | |
| SCHEMBL20716178 | 0.81 | KMT2A (0.50) | ALDH1A1MAOAMAOBSMN1; SMN2L3MBTL1 | |
| SCHEMBL27851118 | 0.81 | MAPT (0.46) | MAOAMAOBRAB9ANPC1 | |
| SCHEMBL10609924 | 0.80 | MAOB (0.48) | MAOAMAOBSMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL28551034 | 0.80 | L3MBTL1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL28552018 | 0.80 | L3MBTL1 (0.61) | MAOAMAOBL3MBTL1RAB9ANPC1 | |
| SCHEMBL28555686 | 0.80 | KMT2A (0.50) | ALDH1A1SMN1; SMN2L3MBTL1RAB9ANPC1 | |
| SCHEMBL28552020 | 0.79 | GPR52 (0.47) | MAOAMAOBSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978216-B | Preparation method of beta-carbonyl sulfone compound | 西南医科大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-111978216-A | Preparation method of beta-carbonyl sulfone compound | 西南医科大学 | 2020-11-24 | — | — | CN | disclosed |
| US-7932403-B2 | Process for preparing pyrrole derivatives and intermediates | RATIOPHARM GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | RATIOPHARM GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | DHCR7, DHPS, CYP46A1 | ALDH1A1 651/4885MAOA 1921/4885MAOB 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.